Streetbeat News

Stock Prices

ATHA

Athira Pharma's Alzheimer's drug candidate failed to show improvement in cognition and function in patients with mild to moderate disease, leading to a decline in its stock price.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 2:28 pm

AMZN

Deep-pocketed investors are showing a bullish sentiment towards Amazon.com (NASDAQ:AMZN) in the options market, with significant call options activity. The price target for AMZN is between $160 and $205, with a current trading price of $173.28. Analysts maintain an Overweight rating with a consensus target price of $233.33.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 2:16 pm

NFLX

Deep-pocketed investors are showing a bearish sentiment towards Netflix (NASDAQ:NFLX) through significant options activity. Despite a divided sentiment, with 47% bearish and 38% bullish, the focus is on a price range between $625 and $1040. Analysts maintain positive ratings with target prices between $750 and $900.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 2:15 pm

CRMT

America's Car-Mart reported a Q1 loss with a 15-cent loss per share, missing profit expectations. Revenues fell 5.2% year-over-year, driven by a decrease in retail units sold. Despite some positive signs like improved gross profit margin and increased interest income, the stock fell over 10%.

Portfolio Pulse from Nabaparna Bhattacharya

September 04, 2024 | 2:09 pm

ALAB

BYD

NDAQ

NVT

Top Wall Street analysts have upgraded their ratings for several companies, including Nasdaq, Inc., nVent Electric, Boyd Gaming Corporation, Sweetgreen, Inc., and Astera Labs, Inc. These upgrades have led to positive movements in their stock prices.

Portfolio Pulse from Avi Kapoor

September 04, 2024 | 2:06 pm

ASST

ATHA

FFIE

OGEN

SHPH

WISA

U.S. stocks showed mixed performance with the Dow Jones slightly up, while NASDAQ and S&P 500 fell. The U.S. trade deficit widened to $78.8 billion in July. Notable stock movements included significant gains for Faraday Future, Asset Entities, and WiSA Technologies, while Athira Pharma, Oragenics, and Shuttle Pharmaceuticals saw substantial declines.

Portfolio Pulse from Avi Kapoor

September 04, 2024 | 2:06 pm

SPY

Federal Reserve's Bostic indicates that price pressures are diminishing, but inflation risks remain. The Fed is focusing equally on inflation and maximum employment. The labor market is loosening, with wage growth stabilizing.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 2:05 pm

RMD

ResMed (NYSE:RMD) has received mixed analyst ratings over the past three months, with a majority being indifferent. Analysts have set a 12-month average price target of $228.17, reflecting a slight increase from previous targets. ResMed's financials show strong net margins and return on equity, but its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 2:01 pm

SPY

The report on durable goods excluding defense for July shows a slight decrease to 10.3% from the previous 10.4%. This minor change may indicate a stable economic environment with no significant impact on the market.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 2:00 pm

ADBE

The article provides an overview of recent analyst ratings for Adobe (NASDAQ:ADBE), highlighting a range of perspectives from bullish to bearish. Over the past three months, 21 analysts have shared their views, with the majority being somewhat bullish. The average 12-month price target is $602.81, with a high of $700.00 and a low of $450.00. Recent analyst actions include both raises and lowers in price targets, reflecting changing market conditions and company performance. Adobe's financial health is strong, with notable revenue growth, high net margins, and effective debt management.

Portfolio Pulse from Benzinga Insights

September 04, 2024 | 2:00 pm